Hypertelorism

Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
Research, Technology, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Patient, Steroid, Pulmonary edema, Lymphocyte, Renal cell carcinoma, PD, Bladder cancer, Colorectal cancer, Clinical trial, CDT, Lung cancer, Head, Serum, NSCLC, Hypertelorism, Lymphocytopenia, Blood, Neoplasm, Avelumab, IL-2, Melanoma, MSI, ASCO, CD25, Poster, IL-6, Society, Artificial intelligence, Therapy, Hand, PD-L1, ADAS, Annual general meeting, MSS, CRS, RCC, Medical imaging

The data will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois.

Key Points: 
  • The data will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois.
  • The durability of the tumor reductions seen in several patients suggests the formation of immune memory of the cancerous cells.
  • “While other developmental IL-2 therapies focus on changing IL-2 itself, AU-007 is a human antibody that is a well-established therapeutic modality.
  • The Phase 2 expansion cohorts of the AU-007 study are continuing to enroll patients with a focus on melanoma and RCC.

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
水曜日, 4月 10, 2024
Hypertelorism, DLT, Safety, Radiation, Pancreatic cancer, TSX, PR, Cancer, LFT, Regulatory T cell, Patient, MDNA, RDE, Duodenal cancer, Toxicity, Melanoma, BCC, MCC, AACR, VLS, MSI-H, PD, NK, Combination therapy, Pharmaceutical industry

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
火曜日, 4月 9, 2024
Toxicity, PR, Combination therapy, VLS, MSI-H, PD, LFT, RDE, Duodenal cancer, Patient, Hypertelorism, Radiation, MCC, MDNA, AACR, TSX, DLT, Pancreatic cancer, Safety, Regulatory T cell, Melanoma, Cancer, BCC, NK, Pharmaceutical industry

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.

 Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate

Retrieved on: 
水曜日, 4月 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Toxicity, Netherlands Cancer Institute, VLS, Therapeutic index, Cell, Patient, ICB, Neoplasm, Immunology, Hypertelorism, Cancer, Infection, Publication, Immunity, IL-2, NKI, CD8, Immune system, Division, NK, Autoimmunity, PD-1, Vaccine

The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.

Key Points: 
  • The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.
  • “These co-published manuscripts are the culmination of several years of great collaboration between Asher Bio scientists and our academic co-founders, Dr.
  • Asher Bio systematically evaluated the properties needed for effective cis-targeting to CD8+ T cells and generated AB248, a CD8+ T cell selective IL-2.
  • To evaluate this hypothesis, Asher Bio’s collaborators at the NKI performed a comprehensive analysis of T cell reinvigoration following treatment with AB248.

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
火曜日, 11月 14, 2023
Georgetown University, Cytokine, Immunity, Research, Non-Hodgkin lymphoma, Therapeutic index, Hypertelorism, Clinical trial, Patient, Tumor microenvironment, Immunotherapy, Therapy, Cancer, SITC, Society, Vaccine, Pharmaceutical industry, Cryptocurrency, Reinsurance, Jazz

WATERTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • “Werewolf has made tremendous strides since last quarter, most notably with the presentation of promising first-in-human data from our lead clinical program, WTX-124.
  • In September 2023, Werewolf hosted a virtual event reviewing the IL-2 landscape and opportunity for WTX-124 among next-generation therapeutic approaches.
  • Financial Results for the Third Quarter of 2023:
    Cash position: As of September 30, 2023, cash and cash equivalents were $130.1 million, compared to $137.5 million as of June 30, 2023.
  • Net loss: Net loss was $8.3 million for the third quarter of 2023, compared to $11.9 million for the same period in 2022.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Retrieved on: 
木曜日, 11月 9, 2023
Renal cell carcinoma, Trae Elston, Anticipation, Liver disease, Research, Annual general meeting, Safety, Research and development, Therapy, Completeness, Colorectal cancer, Hypertelorism, CRC, Liver, PD, FC, ESMO, Administration, Patient, MSS, Tumor microenvironment, Immunotherapy, G&A, RCC, DCR, TME, Melanoma, Cancer, SITC, Roche, R, Oncology, Phase II, Neoplasm, Society, Cell, Pharming, Biopsy, Medical imaging, Pharmaceutical industry, Vaccine, Cryptocurrency

WALTHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Xilio anticipates activating clinical trial sites for the Phase 1 combination dose escalation in the fourth quarter of 2023.
  • As previously announced, Xilio anticipates reporting preliminary safety data from the Phase 1 clinical trial into the third dose level in the fourth quarter of 2023.
  • General & Administrative (G&A) Expenses: G&A expenses were $6.3 million for the quarter ended September 30, 2023, compared to $7.2 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $16.7 million for the quarter ended September 30, 2023, compared to $19.8 million for the quarter ended September 30, 2022.

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

Retrieved on: 
木曜日, 11月 23, 2023
Lung, Hypotension, ODD, Tissue, Clinical trial, Protein, Mortality, Mouse, Edema, Therapy, Blood, Systemic, NIH, Survival, Histamine, Hypertelorism, KOSDAQ, Pharmaceutical industry, Vaccine, TEK tyrosine kinase, Science Advances, Hypoalbuminemia

Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a.

Key Points: 
  • Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a.
  • The results underscore the novel mechanism of action, demonstrating the ability of PMC-403 to reduce vascular leakage associated with ISCLS in the preclinical models.
  • In February 2023, the US FDA granted Orphan Drug Designation (ODD) for PMC-403 for the treatment of Systemic Capillary Leak Syndrome.
  • Dr. Kirk Druey's team shared enthusiasm for the potential breakthrough, underscoring their strong determination to advance into clinical trial.

Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
月曜日, 11月 6, 2023
Hypertelorism, PD, VLS, Trae tha Truth, BCC, MSI-H, MDNA, MCC, Poster, Pharmacodynamics, SITC, Immunotherapy, Radiation, SD, RDE, PK, DLT, Safety, Society, CSCC, PDAC, Patient, Combination therapy, Toxicity, TSX, LFT, Nevus, Medical imaging, Pharmaceutical industry, Vaccine

MDNA11 with uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.

Key Points: 
  • MDNA11 with uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.
  • Following return from a 7 week vacation, a single new lesion was observed and MDNA11 treatment was resumed.
  • Monotherapy expansion part of ABILITY-1 is enrolling patients with metastatic melanoma, non-melanoma skin cancers (CSCC, MCC, and BCC) and MSI-H/dMMR tumors.
  • A copy of the poster and a related slide deck have been posted to the “ Events and Presentations ” page of Medicenna’s website.

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Retrieved on: 
金曜日, 11月 3, 2023
Massachusetts General Hospital, Hypertelorism, Patient, Lymphocytopenia, Incidence, PD, Myalgia, Trae tha Truth, Fatigue, Society for Immunotherapy of Cancer, AST, Fever, FACS, SITC, Immunotherapy, NK, Neoplasm, Webcast, Biopsy, Annual general meeting, IO, Chills, Tumor microenvironment, Safety, Lymphocyte, Cancer, Society, Therapy, ALT, Hospital, Hypoxia, Toxic leukoencephalopathy, Dietary supplement, Pharmaceutical industry

We observed a disease control rate of 50% at higher doses (≥2.8 mg/kg) and 31% across all dose levels in a variety of advanced and IO refractory solid tumors, including cold tumors.

Key Points: 
  • We observed a disease control rate of 50% at higher doses (≥2.8 mg/kg) and 31% across all dose levels in a variety of advanced and IO refractory solid tumors, including cold tumors.
  • Eight (8) patients were treated in Phase 2 monotherapy at a dose level of 1.4 mg/kg Q3W.
  • As of the data cutoff date, 20 patients were continuing treatment with XTX202 across the Phase 1/2 trial.
  • Based on the initial monotherapy data for XTX202, Xilio also plans to explore opportunities for strategic partnerships to evaluate XTX202 as a combination therapy.

Ascendis Pharma Reports Second Quarter 2023 Financial Results

Retrieved on: 
火曜日, 9月 5, 2023
GHD, Pharma, SG, Growth hormone, Pathway, EGFR, NDA, Hypoparathyroidism, Glomerular filtration rate, Achondroplasia, Type, Marketing, Hypertelorism, Patient, Cytokine release syndrome, Southern Transcon, Webcast, R, MAA, Marketing Authorisation Application, Research, FDA, All Our Relations: Finding the Path Forward, OLE, European Commission, Approach, Pharmaceutical industry, Cryptocurrency, EU

Remain on track for European Commission decision on Marketing Authorisation Application (MAA) for TransCon PTH during the fourth quarter of 2023.

Key Points: 
  • Remain on track for European Commission decision on Marketing Authorisation Application (MAA) for TransCon PTH during the fourth quarter of 2023.
  • Ended the second quarter of 2023 with cash, cash equivalents, and marketable securities totaling €431.1 million.
  • Total revenue for the second quarter of 2023 was €47.4 million compared to €6.2 million during the same period in 2022.
  • Ascendis Pharma will host a conference call and webcast today at 4:30 pm Eastern Time (ET) to discuss its second quarter 2023 financial results.